Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

53.91 -0.08 (-0.15%)
Official Closing Price Updated: 7:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,407,638
Open 53.92
Bid (Size) 53.87 (2)
Ask (Size) 53.94 (4)
Prev. Close 53.99
Today's Range 53.52 - 54.41
52wk Range 38.48 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 2.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited... 
Via Benzinga
Sunshine Biopharma Prepares For IND Study Of Novel Cancer Drug That It Expects Could Beat Multidrug-Resistant Cancer
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga

Performance

YTD
-4.84%
-4.84%
1 Month
+6.73%
+6.73%
3 Month
+14.85%
+14.85%
6 Month
+2.88%
+2.88%
1 Year
+39.19%
+39.19%

More News

Read More
Pfizer's Combo Therapy For Fatty Liver Disease Gets FDA Fast Track Status
Via Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Via Benzinga
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
From Pfizer Inc.
Via Business Wire
7 Undervalued Blue-Chip Stocks to Buy for June
Via InvestorPlace
7 of the Best Cheap Stocks to Buy for the Second Half of 2022
Via InvestorPlace
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Fortune 500 List Includes Cryptocurrency Company For The First Time; 30 Return After Missing 2021
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Wednesday, May 25
Via Benzinga
Pfizer to Provide Not-for-Profit Access to Medicines, Vaccines to Low Income Countries
Via Talk Markets
Pfizer To Sell 23 Patented Drugs, Vaccines At Lower Prices To Poorer Countries
Via Benzinga
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
From Pfizer Inc.
Via Business Wire
Which Companies Have Great Reputations With Americans? Hint: Disney Isn't One Of Them!
Via Benzinga
Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies
Via Benzinga
Pfizer's Nearly $7 Billion Acquisition Of Arena Pharma Just Paid Off In A Big Way
Via Investor's Business Daily
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma
Via Benzinga
S&P 500 1Q22 Earnings Recap: Growth Holding Up
Via Talk Markets
Amid Monkeypox Outbreak, This 3X Leveraged ETF Provides Exposure To Health Sector: What To Watch
Via Benzinga
Pfizer, BioNTech Say Three-Dose Covid Vaccine Is 80% Effective In Children Under 5
Via Investor's Business Daily
Morning Brief: Top Financial Stories Dominating on Monday, May 23
Via Benzinga
European Regulator Approves AstraZeneca's COVID-19 shot As Booster
Via Benzinga
Pfizer-BioNTech's Third COVID-19 Vaccine Shot Shows 80% Efficacy In Youngest Children
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.